IMMUNOTHERAPY

Glofitamab and polatuzumab vedotin show promising efficacy and safety in treating relapsed/refractory large B-cell lymphoma, with durable responses reported.

Innovations in cancer immunotherapy highlight the urgent need for effective management of immune-related toxicities, emphasizing precision medicine and interdisciplinary collaboration.

Izalontamab shows promise as a safe treatment for advanced epithelial tumors, demonstrating early antitumor activity in a recent clinical trial.

The EDGE-Gastric trial reveals promising results for domvanalimab and zimberelimab in treating advanced gastric cancer, showcasing durable efficacy and manageable safety.

Vorasidenib shows significant long-term benefits for IDH-mutant glioma patients, enhancing survival and delaying treatment needs post-surgery.

Community-based CAR T-cell therapy expands access to innovative cancer treatments, improving patient outcomes and reducing hospital stays for patients with blood cancers.

Whole-genome sequencing uncovers critical genomic insights in salivary gland cancer, paving the way for targeted therapies and improved patient outcomes.

A novel combination therapy shows promising results for advanced esophageal squamous cell carcinoma, achieving high response rates and manageable safety.

VS-7375 shows promising safety and antitumor activity in advanced solid tumors with KRAS G12D mutation, paving the way for further clinical evaluation.

Exosome-based therapy for glioblastoma receives FDA orphan drug designation, promising targeted treatment and improved delivery methods for cancer care.

FDA designates ZEN-3694 as an orphan drug, offering hope for patients with NUT carcinoma with no current approved therapies.

A recent trial evaluates the impact of dostarlimab on ovarian cancer treatment, revealing modest benefits and no significant safety concerns with niraparib.

The FDA fast-tracks JSKN003, a promising treatment for platinum-resistant ovarian cancer, enhancing development and approval processes for this critical therapy.

Nirogacestat shows significant long-term benefits in treating desmoid tumors, improving survival rates and patient outcomes with manageable side effects.

A phase 1 trial reveals camu camu's safety and potential benefits in melanoma and NSCLC patients undergoing immune checkpoint therapy.

Expert Joe DePinto analyzes the 2025 Cell and Gene Therapy Report, highlighting industry barriers and the growing role of oncologists in patient access.

Combination therapy of percutaneous hepatic perfusion with immune checkpoint inhibitors shows promising survival rates in metastatic uveal melanoma patients.

During a live event, Mark Yarchoan, MD, and participants reviewed adverse event management for 3 different combination regimens for hepatocellular carcinoma.

Immunotherapy shows promise in reducing recurrence rates for high-risk skin cancer, despite mixed results in recent clinical trials.

Ravindra Uppaluri, MD, PhD, discusses findings from the KEYNOTE-689 trial in adult patients with resectable, locally advanced head and neck squamous cell carcinoma.

Ravindra Uppaluri, MD, PhD, discusses the background regarding locally advanced head and neck cancer and what the trial design of KEYNOTE-689 entailed.

Nivolumab plus ipilimumab showed activity in mCRPC, and while adding SBRT was safe, it did not boost efficacy in the CheckPRO trial.